191732-72-6

Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.

Lenalidomide-13C5,15N is a variant of Lenalidomide (T1642) labeled with 15N and 13C. Lenalidomide (T1642) (CC-5013), a derivative of Thalidomide, is an orally active immunomodulatory agent acting as a molecular glue. It serves as a ligand for the E3 ubiquitin ligase cereblon (CRBN), facilitating the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase. Notably, Lenalidomide (T1642) (CC-5013) suppresses the growth of mature B cell lymphomas, including multiple myeloma, and stimulates T cells to release interleukin-2 (IL-2).

Lenalidomide-D5 is a deuterated form of Lenalidomide. Lenalidomide (T1642) (CC-5013) is a derivative of Thalidomide and acts as an orally active immunomodulator in a molecular glue manner. It serves as a ligand for the ubiquitin E3 ligase cereblon (CRBN). Through the CRBN-CRL4 ubiquitin ligase complex, Lenalidomide (T1642) selectively ubiquitinates and degrades the lymphocyte transcription factors IKZF1 and IKZF3. It effectively inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and induces T cells to release interleukin-2 (IL-2).

Lenalidomide (sodium), a Thalidomide derivative, serves as a molecular glue and an orally active immunomodulator. It acts as a cereblon (CRBN) ligand and triggers selective ubiquitination and subsequent degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase. Echoing its specificity, Lenalidomide (sodium) inhibits the proliferation of mature B-cell lymphomas, notably multiple myeloma, and promotes IL-2 secretion from T cells [1] [2].

Lenalidomide-[13C5] (Standard) is a reference standard of Lenalidomide-[13C5] intended for quantitative analysis, quality control, and related biochemical research applications.

Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase.